HIV & Aging: Journal Articles

The symptoms of depression are common among persons living with HIV. Brain-derived neurotrophic factor (BDNF) helps the brain to develop new connections and repair older ones and may have some influences on depression frequency.  For example, antidepressants may work by increasing BDNF in the brain. 

Major depression disorder (MDD) is a common psychiatric comorbidity in persons living with HIV (PLWHIV).  MDD is more common in PLWHIV than in the general population. An existing health care data base was used to investigate factors involved with 30-day hospital readmission frequency.

There are concerns among older persons living with HIV that their risk for Alzheimer’s disease might be increased. One factor that can increase risk is the presence of the APOE-4 gene.

A relationship exists between impaired physical function and increased inflammation. This study addresses the question - is there is a relationship between gut microbiome and physical function level in those with and without HIV.

Although PrEP has been shown to be effective with short term use, a study covering 3 years has found continuing success in reducing new HIV infections.

Telomere length decreases with age. Also, there is shortening of telomere length associated with HIV infection.  This study addresses the question as to whether immediate treatment for new HIV diagnosis can reduce telomere shortening.

Cognitive impairment and carotid artery stiffness characterize many older adults with HIV. A risk for Alzheimer’s disease may be poor blood flow to the brain.

Those with HIV have an increased risk of cardiovascular disease. A study using CT (computed tomography) compared those with and without HIV for the frequency of calcium deposits in coronary artery plaques.

Each year we collect the published articles that address the topic of older adults living with HIV/AIDS.
The number is again higher this year and are about 1000 in number.

Previous studies have shown that cabotegravir and rilpivirine (Cabenuva) injections every 4 weeks provided a similar result to oral ART therapy. This regimen has received FDA approval.  The question is whether a longer period between injections is possible.


Purpose of this Program: The AAHIVM, ACRIA and AGS (collectively, the “Sponsors,” “we” or “us”) are sponsors of this Website and through it seek to address the unique needs and challenges that older adults of diverse populations living with HIV face as they age. However, the information in this Website is not meant to supplant the advice provided in a doctor-patient relationship.

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.



Phone: 202-659-0699
Fax: 202-659-0976


AAHIVM National Office
1627 Eye St NW Suite 835
Washington, D.C. 20006


The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.